Avidicure is hiring a Principal Scientist in Leiden
The role is based with the team in Leiden and targets candidates who share its passion for creating a new standard of care through antibodies. Agency applications are not accepted.
See the latest news and media coverage for Avidicure. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing immune-modulating antibody therapeutics
avidicure.comLast updated
The role is based with the team in Leiden and targets candidates who share its passion for creating a new standard of care through antibodies. Agency applications are not accepted.
The role is based in Leiden and seeks candidates passionate about harnessing antibodies. Agency applications are not accepted.
The role joins its team in Leiden and suits candidates passionate about harnessing the power of antibodies.
Novel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system in non-small cell lung cancer...
Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer indications The company will present at upcoming...
AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potent monotherapy with broad application in oncology Lead product AVC-S-101 is a TROP2-targeting...
Avidicure is a new biotechnology company that has been launched on the back of a $50 million seed financing round for developing a new multifunctional...
Track Avidicure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Avidicure and other trending companies.